New drug cocktail shows promise for kids with resistant cancers

NCT ID NCT01282697

Completed Disease control Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a combination of two drugs—rapamycin and irinotecan—in 42 children and young adults (ages 1–21) with solid tumors that did not respond to standard treatments. The main goal was to find the safest dose and understand side effects. The approach aims to block blood vessel growth in tumors and stop their progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rapamycin and irinotecan
What this could lead to: If this works, it could point toward a new treatment option for children with solid tumors that haven't responded to standard therapies.
What could go wrong: This is a very early phase I trial with only 42 children, focused on safety and dosing—not yet on effectiveness. The combination may cause significant side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REFRACTORY SOLID TUMORS IN CHILDREN

Contacts and locations

Locations

CHU La Timone

Marseille, 13005, France
CHU Mère-Enfants

Nantes, 44093, France
Centre Oscar Lambret

Lille, 59020, France
Hôpital des Enfants

Toulouse, 31059, France
Hôpital des Enfants - Groupe Hospitalier Pellegrin

Bordeaux, 33076, France
Hôpitaux Universitaires de Strasbourg

Strasbourg, 67098, France
Institut Curie

Paris, 75005, France
Institut Gustave Roussy

Villejuif, 94805, France
Institut Hémato-Oncologie Pédiatrique (IHOP)

Lyon, 67008, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.